...
首页> 外文期刊>Tropical Medicine and Infectious Disease >Screening for Parasitic Infection and Tuberculosis in Immunosuppressed and Pre-Immunosuppressed Patients: An Observational Study
【24h】

Screening for Parasitic Infection and Tuberculosis in Immunosuppressed and Pre-Immunosuppressed Patients: An Observational Study

机译:免疫抑制和预免疫抑制患者寄生虫感染和结核病的筛选:观察研究

获取原文
           

摘要

Reactivation of latent tuberculosis infection (LTBI) or latent parasitic infection (LPI) during drug-induced immunosuppression can have serious consequences. The Division of tropical and humanitarian medicine of the Geneva University Hospitals runs a specific consultation for parasitic screening of immunosuppressed or pre-immunosuppressed patients. We sought to determine the seroprevalence of LTBI and LPI in such patients and explore its relationship with country of origin or previous travel in a retrospective, single-centre observational study from 2016 to 2019. Demographic data, travel history, ongoing treatments and results of the parasitological (Strongyloides stercoralis, Trypanosoma cruzi, Echinococcus multilocularis, Entamoeba histolytica and Leishmania spp.) and TB screening were collected to calculate LPI or LTBI prevalence. Risk factors for LTBI and strongyloidiasis were analysed using Poisson regression with robust variance. Among 406 eligible patients, 24/353 (6.8%) had LTBI, 8/368 (2.2%) were positive for Strongyloides stercoralis infection, 1/32 (3.1%) was positive for Entamoeba histolytica and 1/299 (0.3%) was positive for Leishmaniasis. No cases of Trypanosoma cruzi (0/274) or Echinococcus multilocularis (0/56) infection were detected. Previous travel to or originating from high-prevalence countries was a risk factor for LTBI (PR = 3.4, CI 95%: 1.4–8.2 and 4.0, CI 95%: 1.8–8.9, respectively). The prevalence of serological Strongyloidiasis in immunosuppressed patients is lower in comparison to those without immunosuppression (PR = 0.1, CI 95%: 0.01–0.8). In conclusion, screening before immunosuppression needs to be individualized, and LTBI and LPI need to be ruled out in patients who originate from or have travelled to high-prevalence countries. The sensitivity of strongyloidiasis serology is reduced following immunosuppression, so an algorithm combining different tests or presumptive treatment should be considered.
机译:药物诱导的免疫抑制期间潜在结核感染(LTBI)或潜伏的寄生虫感染(LPI)的再活化会产生严重后果。日内瓦大学医院的热带和人道主义医学司对免疫抑制或预免疫抑制患者的寄生筛查进行了特定的咨询。我们试图在这些患者中确定LTBI和LPI的SEROPREVALING,并在2016年至2016年到2016年开始探索其与起源国或以前旅行的关系。人口统计数据,旅游历史,正在进行的治疗和结果收集寄生虫学(睾丸STERCORALI,锥虫瘤瘤,海螺肽多联,entamoEBA组织olytica和Leishmania SPP。)和TB筛选以计算LPI或LTBI流行率。使用泊松回归具有强大方差的泊松回归分析了LTBI和抗弓首虫病的危险因素。在406名符合条件的患者中,24/353(6.8%)患有LTBI,8/368(2.2%)对抗肌腱感染阳性阳性,1/32(3.1%)对于entamoeba histolytica阳性和1/299(0.3%)是阳性的对利什曼病的阳性。没有检测到胰蛋白酶瘤瘤瘤瘤瘤或echinococcus multiCularis(0/56)感染病例。以前的旅行或起源于高流行国家是LTBI的危险因素(PR = 3.4,CI 95%:1.4-8.2和4.0,CI分别为95%:1.8-8.9)。与没有免疫抑制的人相比,免疫抑制患者血管素抗抑郁患者中的患病率降低(PR = 0.1,CI 95%:0.01-0.8)。总之,在免疫抑制前筛选需要个性化,并且需要在源自或已经向高流行国家旅行的患者中排除LTBI和LPI。在免疫抑制后,抗施酮血管病的敏感性降低,因此应考虑结合不同测试或推定治疗的算法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号